PubMed
Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
Sikiric et al., 2018
Pentadecapeptide BPC 157
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a gastric juice protein, researched extensively for accelerating tissue healing, gut repair, and tendon recovery. Animal studies demonstrate dose-dependent healing of tendons, ligaments, bones, muscles, and intestinal tissue, along with anti-inflammatory and angiogenic effects. Not FDA-approved; placed on the FDA's 503A prohibited bulk substances list in 2023.
Overall check-ins
Trackers & reports
Overview
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a gastric juice protein, researched extensively for accelerating tissue healing, gut repair, and tendon recovery. Animal studies demonstrate dose-dependent healing of tendons, ligaments, bones, muscles, and intestinal tissue, along with anti-inflammatory and angiogenic effects. Not FDA-approved; placed on the FDA's 503A prohibited bulk substances list in 2023.
Community
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 94% said they felt similar to their last entry, 6% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 50 days · Based on 47 repeat reporters
Research
PubMed
Sikiric et al., 2018
PubMed
Chang et al., 2019
PubMed
Vukojevic et al., 2022
ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Seiwerth et al., 2018
PubMed
Ilic et al., 2011
PubMed
Lee et al., 2021
PubMed
Yuan et al., 2026
PubMed
Mayfield et al., 2026
PubMed
Rahman et al., 2026
Tools
More ways to learn about BPC-157 from observational PeptIQ data.
Help
This page summarizes 128 anonymized self-reports from PeptIQ users who track BPC-157, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
10 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
This wiki does not assess safety or recommend use. BPC-157 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
This wiki summarizes observational community reports and linked citations for BPC-157. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for BPC-157 for study-level context — not medical advice.
BPC-157 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
Safety data quality for BPC-157 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
This page links 10 indexed sources for BPC-157. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.